Efficacy and tolerability of high dose interleukin-2 (HD IL-2) after disease progression on targeted therapy (TT) for metastatic renal cell carcinoma (mRCC).

被引：0
|
作者：
Vu, Peter
Mai, Hanh P.
Adams, William
Gonzalez, Beverly
Kliethermes, Stephanie
Clark, Joseph
Henry, Elizabeth
机构：
[1] Loyola Univ Med Ctr, Maywood, IL 60153 USA
[2] Loyola Univ Med Ctr, Chicago, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e16064
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16064
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Impact of targeted therapy (TT) on survival of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2): Analysis of the PROCLAIM HD IL-2 National Registry
    Clark, Joseph
    Morse, Michael
    Wong, Michael K. K.
    McDermott, David F.
    Kaufman, Howard
    Daniels, Gregory A.
    Hua, Hong
    Aung, Sandra
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Conditional survival (CS) of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2)
    Parikh, Kinjal
    Stenehjem, David D.
    Sendilnathan, Arun
    Crispin, Hilda
    Van Atta, Joan
    Batten, Julia Anne
    Sageser, Daniel
    Grossmann, Kenneth F.
    Wang, Junfeng
    Samlowski, Wolfram E.
    Tantravahi, Srinivas Kiran
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [3] Extension of survival in patients with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2) immunotherapy in the post 2006 targeted therapy era
    Clark, Joseph I.
    Wong, Michael K.
    Daniels, Gregory A.
    Kaufman, Howard L.
    McDermott, David F.
    Morse, Michael A.
    Aung, Sandra
    BJU INTERNATIONAL, 2014, 114 : 5 - 5
  • [4] High-dose interleukin-2 (HD IL-2) for metastatic renal Cell carcinoma (mRCC): Contemporary utilization trends in the United States
    Allard, Christopher B.
    Gelpi-Hammerschmidt, Francisco
    Harshman, Lauren Christine
    Faiena, Izak
    Modi, Parth K.
    Chung, Benjamin I.
    Singer, Eric A.
    Chang, Steven L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [5] Conditional survival (CS) of metastatic renal cell carcinoma (mRCC) patients treated with high-dose interleukin-2 (HD IL-2)
    Straubhar, Alli M.
    Stenehjem, David D.
    Parikh, Kinjal
    Merriman, Joseph
    Crispin, Hilda
    Sendlinathan, Arun
    Van Atta, Joan
    Batten, Julia A.
    Agarwal, Archana M.
    Tantravahi, Srinivas Kiran
    Samiowski, Wolfram E.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Clinical benefit (CB) of high-dose interleukin-2 (HD IL-2) in clear cell (cc) metastatic renal cell carcinoma (mRCC)
    Agarwal, Neeraj
    Parikh, Kinjal
    Tantravahi, Srinivas Kiran
    Crispin, Hilda
    Van Atta, Joan
    Batten, Julia Anne
    Sageser, Daniel
    Samlowski, Wolfram E.
    Grossmann, Kenneth F.
    Wang, Junfeng
    Stenehjem, David D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [7] Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2).
    Clark, Joseph
    Morse, Michael A.
    Wong, Michael K. K.
    McDermott, David F.
    Kaufman, Howard
    Daniels, Gregory A.
    Perritt, Jessica C.
    Hua, Hong
    Aung, Sandra
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [8] Association between rigors and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose interleukin-2 (HD IL-2).
    Batten, Julia Anne
    Samlowski, Wolfram E.
    Parikh, Kinjal
    Sendilnathan, Arun
    Crispin, Hilda
    Van Atta, Joan
    Sageser, Daniel
    Grossmann, Kenneth F.
    Wang, Junfeng
    Tantravahi, Srinivas Kiran
    Stenehjem, David D.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [9] High dose Interleukin2 (HD IL2) in metastatic renal cell carcinoma (mRCC) after prior therapy: A single centre experience
    Chow, Shien
    Leach, Rebecca
    Spencer-Shaw, Andrea
    Shaheen, Fadhel
    Thistlethwaite, Fiona C.
    Hawkins, Robert E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] HIGH-DOSE INTERLEUKIN-2 (HD IL2) ARMED WITH PATHOLOGY-BASED SELECTION CRITERIA: A REAL OPTION IN TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) AFTER TARGETED THERAPY
    Chow, S.
    Galvis, V.
    Evans, M.
    Chan, K.
    Spencer-Shaw, A.
    Leach, R.
    Keene, K.
    Shablak, A.
    Shanks, J.
    Thistlethwaite, F.
    Hawkins, R.
    ANNALS OF ONCOLOGY, 2014, 25
12345